Infectious Diseases and Immunology Department, Hôpital Universitaire Henri Mondor, Assistance Publique Hôpitaux de Paris - Université Paris Est Créteil, France.
Vaccine Research Institute, Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France; Univ Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France.
Vaccine. 2023 Feb 24;41(9):1550-1553. doi: 10.1016/j.vaccine.2023.01.064. Epub 2023 Jan 30.
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vaccine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 therapies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4Th1T cell responses while the effect CD8 + T cell responses was marginal.
接受抗 CD20 抗体治疗的患者显示出 BNT162b2 加强剂量的疗效有限。患有淋巴瘤的患者将此类免疫疗法与细胞毒性化疗联合使用，这可能导致对疫苗接种的免疫反应发生更大的改变。我们在此报告了在我们中心接受抗 CD20 治疗和细胞毒性化疗治疗淋巴样恶性肿瘤的一小部分患者中，第三剂疫苗对 T 细胞特异性反应的影响。我们的结果表明，在这些严重免疫抑制的患者中，第三剂可以改善 CD4Th1T 细胞反应的扩增，而 CD8+T 细胞反应的效果则微不足道。
